15 January 2019 in Science Signaling
Low-affinity ligands stimulate T cell responses when sequential antigen recognition events occur in nearby membrane regions.
1 December 2020 in The Journal of Immunology
IL-10 is a potent anti-inflammatory cytokine capable of suppressing a number of proinflammatory signals associated with intestinal inflammatory diseases, such as ulcerative colitis and Crohn9s disease. Clinical use of human IL-10 (hIL-10) has been limited by anemia and thrombocytopenia following systemic injection, side effects that might be eliminated by a gut-restricted distribution. We have identified a transcytosis pathway used by cholix, an exotoxin secreted by nonpandemic forms of the intestinal pathogen Vibrio cholerae. A nontoxic fragment of the first 386 aa of cholix was genetically fused to hIL-10 to produce recombinant AMT-101. In vitro and in vivo characterization of AMT-101 showed it to efficiently cross healthy human intestinal epithelium (SMI-100) by a vesicular transcytosis process, activate hIL-10 receptors in an engineered U2OS osteosarcoma cell line, and increase cellular phospho-STAT3 levels in J774.2 mouse macrophage cells. AMT-101 was taken up by inflamed intestinal mucosa and activated pSTAT3 in the lamina propria with limited systemic distribution. AMT-101 administered to healthy mice by oral gavage or to cynomolgus monkeys (nonhuman primates) by colonic spray increased circulating levels of IL-1R antagonist (IL-1Ra). Oral gavage of AMT-101 in two mouse models of induced colitis prevented associated pathological events and plasma cytokine changes. Overall, these studies suggest that AMT-101 can efficiently overcome the epithelial barrier to focus biologically active IL-10 to the intestinal lamina propria. Key Points Human IL-10 genetically fused to Chx exotoxin transcytosis domain (AMT-101). AMT-101 was tested in human cell models in vitro and in rodents and nonhuman primates in vivo. Oral dosing targeted intestinal lamina propria to suppress inflammation without systemic PK.
5 October 2026 in Cancer Research
Human papillomavirus (HPV) plays a pivotal role in various malignancies, including cervical, anogenital, head, and neck cancers. Despite the availability of highly effective prophylactic vaccines, many individuals remain susceptible to HPV-driven cancers because of barriers such as limited vaccine access, lack of awareness, or personal preferences. Current treatments primarily target lesions without eradicating persistent HPV infections, leading to an increased risk of subsequent HPV-associated cancers. This scenario underscores an urgent need for innovative treatment modalities aimed at eliminating persistent HPV infections. In this study, we developed NTX250, a messenger RNA (mRNA)–based therapeutic platform engineered to deliver HPV type 16 (HPV16) E6 and E7 antigens, in conjunction with the immunomodulators interleukin (IL) 12 and LIGHT. A lipid and ionizable peptoid nanoparticle system facilitated precise intralesional delivery of NTX250. Localized NTX250 administration in HPV16-transformed tumor-bearing models led to complete tumor regression and established durable, antigen-specific immune memory. Replacing the HPV antigens with a construct comprising colorectal cancer cell–specific neoepitopes enabled stimulated antitumor immunity and suppressed tumor growth, supporting the generalizability of the approach. Overall, NTX250 represents a promising nonsurgical immunotherapy platform that is capable of eliciting robust and targeted antitumor immune responses across diverse malignancies. This adaptable mRNA nanoparticle approach enables the codelivery of tumor-specific antigens and immunomodulators, with the potential to target tumor-associated antigens beyond HPV. Significance: NTX250 is an mRNA-based therapeutic platform that offers a non-invasive approach to eradicate persistent HPV infections and induce strong anti-tumor immune responses, fulfilling a critical need in HPV-related cancer treatment.